<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of intravenous immune globulin (IVIG) therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of intravenous immune globulin (IVIG) therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of intravenous immune globulin (IVIG) therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Ballow, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nadine Shehata, MD, MSc, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> derived from the plasma of paid donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders.</p><p>This topic will review the uses, proposed mechanisms of action, and administration of intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG).</p><p>Additional topic reviews discuss the adverse effects of IVIG therapy and the administration of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> by subcutaneous and intramuscular routes. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Several terms are used for <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> preparations according to the route of administration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVIG</strong> – Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (immune globulin, intravenous [human]) will be referred to as "IVIG" in this review because this term is commonly used by clinicians, although the abbreviation used by industry and various regulatory agencies is "IGIV" (immune globulin intravenous).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCIG</strong> – Subcutaneous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (SCIG) is used for products administered subcutaneously, although immune globulin subcutaneous (IGSC) is the term preferred by regulatory agencies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IMIG</strong> – Intramuscular <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IMIG) is used for products administered intramuscularly.</p><p></p><p>Multiple products are available for each preparation, which vary in concentration of immunoglobulin G (IgG), additives and stabilizers, and IgA content. (See <a class="local">'Production and composition'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperimmune globulin</strong> – Hyperimmune globulin refers to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> prepared from plasma of individuals with high titers of specific antibodies to certain pathogens and/or individuals who are immunized or through natural exposure to specific antigens. Some hyperimmune globulins for infectious diseases are of animal origin. (See  <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'Hyperimmune globulins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-D </strong><strong>immune globulin</strong> – Anti-D immune globulin (also called Rho[D] <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>; eg, HyperRHO, MICRhoGAM, RhoGAM, WinRho) is a type of hyperimmune globulin against the RhD antigen on red blood cells (RBCs). It is used to prevent hemolytic disease of the fetus and newborn (HDFN) and in some cases to treat immune thrombocytopenia (ITP). (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a> and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Anti-D as an alternative to IVIG'</a>.)</p><p></p><p class="headingAnchor" id="H158488"><span class="h1">MECHANISMS OF ACTION</span></p><p class="headingAnchor" id="H158519"><span class="h2">Protection against infection</span><span class="headingEndMark"> — </span>When given in the setting of hypogammaglobulinemia, antibody deficiency disorders, and/or other immunodeficiency states, IVIG (and other <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> preparations) acts by providing adequate concentrations of antibodies against a broad range of pathogens by providing passive immunity. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p>Hyperimmune globulins provide specific passive immunity, typically in the setting of a known or expected exposure. These products are generated from individuals (or rarely animals, such as equine botulinum antitoxin and equine <a class="drug drug_general" data-topicid="8900" href="/z/d/drug information/8900.html" rel="external">diphtheria antitoxin</a> antibodies) with high titer antibodies to the implicated organism (or toxin). They impart temporary, passive immunity to the target pathogen. It is theoretically possible to produce a hyperimmune globulin to any organism from convalescent plasma, which can safely be used as passive immunization. Intravenous hyperimmune globulins are available for treatment of infantile botulism, prevention and treatment of vaccinia virus infection, prevention of hepatitis B virus infection in liver transplantation, and prevention and treatment of cytomegalovirus infections in patients undergoing organ transplantation. (See  <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'Hyperimmune globulins'</a>.)</p><p class="headingAnchor" id="H164707"><span class="h2">Alloimmunization</span><span class="headingEndMark"> — </span>In the setting of pregnancy in an RhD-negative woman with a fetus that is potentially RhD-positive, the use of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> works by a mechanism that is as yet unproven. Possibilities include rapid macrophage-mediated clearance of anti-D-coated red blood cells and/or downregulation of antigen-specific B cells before an immune response occurs [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p class="headingAnchor" id="H158537"><span class="h2">Suppression of inflammatory/autoimmune processes</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> has several potential antiinflammatory and immunomodulatory effects [<a href="#rid3">3-5</a>]. The relative contribution of these in any individual patient is difficult to assess because different mechanisms may dominate in different diseases. Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Interaction with/blocking of Fc receptors on phagocytic cells in the spleen and liver such as splenic macrophages [<a href="#rid6">6-9</a>]. In immune thrombocytopenia (ITP), this effect may prevent reticuloendothelial uptake of autoantibody-coated platelets [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of dendritic cell differentiation and maturation [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of proinflammatory subsets of peripheral blood monocytes (CD14<sup>+</sup>CD16<sup>++</sup>) and suppression of cytokine production by these cells [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppression or neutralization of cytokines by specific antibodies in the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blockade of leukocyte adhesion molecule binding to the vascular endothelium. In a murine model of sickle cell disease, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> reversed vaso-occlusive crises by inhibiting the binding of leukocytes to the vascular endothelium, in turn leading to improved blood flow [<a href="#rid14">14</a>]. This mechanism may also play a role in the effects of IVIG in Kawasaki disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blockade of Fas ligand-mediated apoptosis by anti-Fas antibodies in the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. In a study of patients with toxic epidermal necrolysis (TEN), associated with keratinocyte death and epithelial desquamation, patient serum was found to contain lytically active FAS ligand, and IVIG was able to block Fas-mediated cell death in vitro [<a href="#rid15">15</a>]. In a companion study in 10 patients, IVIG rapidly reversed TEN disease progression [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction of inhibitory Fc-gamma-RIIB receptors on effector macrophages. This effect on the Fc-gamma-RIIB receptor was linked to the sialylation of the glycan component in the CH2 domain of the immunoglobulin G (IgG) molecule [<a href="#rid16">16</a>]. In a mouse model, a C-type lectin receptor on dendritic cells and macrophages was required for the antiinflammatory effects of IgG by binding IgG through the sialylated Fc domain [<a href="#rid8">8,17</a>]. The mediator involved in this process was interleukin (IL)-33 from dendritic cells, which in turn increased the production of IL-4 from basophils that lead to the upregulation of the Fc-gamma-RIIB receptor on effector macrophages and the inhibitory antiinflammatory effects. Although the data in human autoimmune disease are limited, the peripheral blood monocytes in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with high-dose <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> showed upregulation of the Fc-gamma-RIIB receptor [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supply of anti-idiotypic antibodies directed against idiotypes on circulating autoantibodies. Anti-idiotypic antibodies in the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may bind either to circulating autoantibodies, resulting in increased clearance, or to B cell immunoglobulin receptors, leading to downregulation of antibody production. In individuals with acquired hemophilia due to autoantibodies against factor VIII (ie, acquired factor VIII inhibitors), this may account for the ability of IVIG to reduce the inhibitor titer. (See  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)", section on 'Eliminate the inhibitor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of neutralizing antibodies to microbial toxins.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In staphylococcal toxic shock syndrome, severe group A streptococcal infections, and Kawasaki disease, neutralizing antibodies directed against staphylococcal toxin and streptococcal "superantigens" (proteins that can bind simultaneously to MHC class II antigens and to the non-antigen-binding region of T cell receptors) and may in turn reduce cytokine production [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention", section on 'Intravenous immune globulin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In Shiga toxin-mediated hemolytic uremic syndrome (ST-HUS), for example, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> may provide antibodies against the toxin; however, a role for IVIG in ST-HUS has not been established [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effects on the complement system, such as the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Solubilization and clearance of immune complex deposits and/or inhibition of the binding of active complement components such as C4b and membrane attack complex to target tissues [<a href="#rid7">7</a>]. This may be important in immune complex disorders such as membranous nephropathy and dermatomyositis [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supply of an alternate binding site or "sink" for the complement component C3b, diverting it from binding to targets of complement activation [<a href="#rid24">24</a>]. The inflammatory actions of the complement fragments C3a and C5a may also be neutralized via a physical association between these anaphylatoxins and the constant region of F(ab)'2 [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in regulatory T cells (Tregs). In a mouse model of multiple sclerosis, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> abrogated disease progression by expanding CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Tregs and inhibiting the proinflammatory Th17 pathway [<a href="#rid26">26</a>]. This mechanism of IVIG was not dependent on the Fc domain and sialylation. Other models have demonstrated a requirement for IgG sialylation [<a href="#rid27">27</a>]. Many animal models have shown that IVIG promotes expansion of FoxP3<sup>+</sup> Tregs and downregulates the Th17 pathway. The mechanism by which IVIG induces Tregs may be through the prostaglandin E2 pathway as demonstrated in human dendritic cells in vitro [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'Suppression'</a>.)</p><p></p><p class="bulletIndent1">Several studies in human disease support this mechanism:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with Kawasaki disease treated with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> show increased numbers of Tregs and increased expression of genes related to Treg activation [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with autoimmune disease treated with high-dose <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> have increased activation of circulating Tregs [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Accelerated clearance of pathogenic IgG. This may occur through increases in the total plasma concentration of IgG, which saturate the FcRn receptor on vascular endothelial cells of the IgG transport system [<a href="#rid20">20,32,33</a>]. Once this receptor becomes saturated, IgG is no longer protected and is degraded according to its relative serum level. The FcRn receptor accounts for the long half-life of serum IgG. This mechanism accounted for approximately 50 percent of the enhanced clearance of antiplatelet antibodies in a mouse model of ITP, and it may partially account for the long-term effects of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in ITP. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.) </p><p></p><p>Given the multiple antiinflammatory effects of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, probably more than one mechanism is responsible for its immune modulating effects in autoimmune disease. In any given disease state, it is not clear whether all the IgG molecules present in the polyclonal IgG preparation (or only a small sub-fraction of the IgG molecules) are responsible for the clinically beneficial effect. For example, when IVIG is used to neutralize certain autoantibodies or anti-HLA antibodies, only that small fraction of IgG molecules with specific anti-idiotypic activity are likely to be needed [<a href="#rid34">34</a>]. In addition, laboratory evidence suggests that some IgG molecules with heavily sialylated Fc regions may preferentially exert antiinflammatory effects. Nevertheless, available commercial products are not characterized for, nor differentiated by, their content of antibodies of different specificities or chemical compositions.</p><p class="headingAnchor" id="H742000051"><span class="h1">CLINICAL USES</span></p><p class="headingAnchor" id="H5"><span class="h2">Uses for IVIG</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may be administered as a component of therapy for several categories of disorders [<a href="#rid35">35</a>]. </p><p>The list below is representative and not intended to be comprehensive, as clinical applications continue to evolve.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunodeficiency states, both primary and secondary</strong> – Examples include inborn errors of immunity affecting antibody production or function, chronic lymphocytic leukemia (CLL), multiple myeloma, reduced immune function following hematopoietic stem cell transplantation, and states of severe protein loss. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimmunologic disorders</strong> – Examples include chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, Guillain-Barré syndrome, and myasthenia gravis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune/inflammatory conditions</strong> – Examples include immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia, acquired von Willebrand syndrome (aVWS) caused by autoantibodies against von Willebrand factor, Kawasaki disease, and multisystem inflammatory disease in children (MIS-C) associated with coronavirus disease 2019 (COVID-19).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections and infection-related disorders</strong> – Examples include chronic parvovirus infection complicated by anemia, toxic shock syndrome, and measles postexposure prophylaxis (if the patient is immunocompromised or nonimmune). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alloimmune processes</strong> – Examples include hemolytic disease of the fetus and newborn (HDFN), post-transfusion purpura, antibody-mediated organ transplant rejection, and hyperhemolytic crisis in individuals with sickle cell disease who have received transfusions.</p><p></p><p>One medical center reviewed the use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> during a single calendar year. A total of 194 patients received 48,230 grams of IVIG [<a href="#rid36">36</a>]. The six most common conditions for which IVIG was used included:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic neuropathy (29 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary hypogammaglobulinemia (18 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>ITP (10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogammaglobulinemia (9 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Renal transplantation (6 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Myasthenia gravis (5 percent)</p><p></p><p class="headingAnchor" id="H97043703"><span class="h2">Uses for hyperimmune globulin</span><span class="headingEndMark"> — </span>Hyperimmune globulins are used in the setting of specific exposures. These products can be administered intravenously or intramuscularly.</p><p>During the 2019-2020 coronavirus disease (COVID-19) pandemic, community blood centers, academic institutions, and government organizations in the United States and around the world established programs for individuals who have recovered from SARS-CoV-2 infection to donate convalescent plasma, from which hyperimmune globulin can be manufactured. (See  <a class="medical medical_review" href="/z/d/html/128321.html" rel="external">"COVID-19: Convalescent plasma and hyperimmune globulin"</a>.)</p><p>Hyperimmune globulin and other immunoglobulin products prepared from convalescent plasma are also under study, although the characteristics of the products are not well described [<a href="#rid37">37,38</a>]. </p><p>Other hyperimmune globulin products used for infection prophylaxis and therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Various products (eg, <a class="drug drug_general" data-topicid="9442" href="/z/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> [VariZIG]; <a class="drug drug_general" data-topicid="9315" href="/z/d/drug information/9315.html" rel="external">cytomegalovirus immune globulin</a> [CMVIG]) may be given to hematopoietic cell transplantation (HCT) recipients who have not yet been re-immunized against certain viral infections, as postexposure prophylaxis. VariZIG may also be administered to immunodeficient patients after exposure. (See  <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8520" href="/z/d/drug information/8520.html" rel="external">Hepatitis B immune globulin</a> (HBIG) may be given to an infant born to a hepatitis B virus (HBV)-infected mother, to an individual exposed to HBV who was not previously vaccinated, or to an HBV-infected individual undergoing liver transplantation. (See  <a class="medical medical_review" href="/z/d/html/3647.html" rel="external">"Prevention of hepatitis B virus and hepatitis C virus infection among health care providers"</a> and  <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents", section on 'HBsAg-positive mother or mother with other evidence of HBV infection'</a> and  <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">"Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients", section on 'Immunoprophylaxis for high-risk patients'</a> and  <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">"Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients", section on 'Strategies to prevent HBV reinfection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">Rabies immune globulin</a> (prepared from human or horse plasma) may be used in individuals exposed to rabies virus (or those at risk for having been exposed). (See  <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">"Rabies immune globulin and vaccine"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8708" href="/z/d/drug information/8708.html" rel="external">Botulism immune globulin</a> may be used for infants less than one year old diagnosed with botulism. (See  <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">"Botulism", section on 'Botulinum immune globulin for infant botulism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9983" href="/z/d/drug information/9983.html" rel="external">Tetanus immune globulin</a> is given to individuals with tetanus and may be used along with vaccination for certain individuals with puncture wounds. (See  <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">"Infectious complications of puncture wounds", section on 'Tetanus immunization'</a> and  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus", section on 'Neutralization of unbound toxin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10332" href="/z/d/drug information/10332.html" rel="external">Vaccinia immune globulin</a> may be available for selected cases of inadvertent inoculation or complications of vaccinia. (See  <a class="medical medical_review" href="/z/d/html/4930.html" rel="external">"Myopericarditis", section on 'Vaccinia-associated myopericarditis'</a>.)</p><p></p><p>The use of anti-D immune globulin to prevent RhD alloimmunization and reduce the risk of hemolytic disease of the fetus and newborn (HDFN) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p class="headingAnchor" id="H163794"><span class="h1">PRETREATMENT TESTING</span><span class="headingEndMark"> — </span>Pretreatment laboratory testing for evidence of viral infections (eg, hepatitis), and autoantibodies (depending on the patient's clinical presentation) is performed to determine whether the patient is exposed/infected with a pathogen or has an underlying autoimmune process, since once they receive an immunoglobulin product the source of pathogen antibody or autoantibodies cannot be determined.</p><p>For most patients, we obtain a complete blood count (CBC), hepatic transaminases, metabolic panel including glucose, serum creatinine, and urinalysis before initiating <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. This may identify pre-existing infection or risk for complications (see  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>) before the IVIG is administered and allows appropriate evaluation if required.</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with abnormal baseline testing, evaluation for bloodborne pathogens may be appropriate (eg, hepatitis). When indicated, testing for bloodborne pathogens should be done before starting <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy because serologic tests may become positive following IVIG administration due to the passively transferred antibodies in the IVIG, especially common viruses such as Epstein-Barr virus (EBV), cytomegalovirus (CMV), and hepatitis B virus (HBV). However, urgent therapy should not be delayed for this testing.</p><p></p><p class="bulletIndent1">The overall risk of transmission of viruses or other pathogens from <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is extremely low (see  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Infectious risks'</a>). In most cases, this information is useful for identifying infections that require treatment rather than for "look back" purposes, in which attempts are made to identify a specific donor responsible for the transmission. Such lookback studies are extremely difficult, if not impossible, when dealing with a product in which plasma components from thousands of donors is pooled.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with hypogammaglobulinemia (eg, primary immunodeficiencies) should be evaluated using NAT-based testing because they may have impaired production of specific antibodies, and serologic testing will be uninformative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals without hypogammaglobulinemia can be evaluated using serologic or NAT-based testing, if needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some individuals with normal baseline testing may also benefit from information about pre-existing viral infections. As an example, it may be important to know whether a potential transplant recipient has been infected with CMV or viruses that might become reactivated during immunosuppressive therapy.</p><p></p><p>Direct antiglobulin (Coombs) testing (DAT) may be useful in some patients depending on their disease, especially certain types of autoimmune disorders, prior to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy. This is because the testing for autoantibodies may become positive or uninterpretable following IVIG administration.</p><p>The intervention for positive Coombs testing depends on whether the finding was expected (eg, known autoimmune hemolytic anemia) or unexpected. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Hemolysis'</a>.)</p><p class="headingAnchor" id="H24252526"><span class="h1">PRODUCTION AND COMPOSITION</span><span class="headingEndMark"> — </span>Production of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> takes approximately nine months. The process begins with pooled human plasma from several thousand (&gt;10,000; not to exceed 60,000) screened paid and volunteer donors [<a href="#rid35">35</a>]. Products used in the United States are derived from the plasma of donors in the United States. </p><p>Cold alcohol fractionation (by the Cohn or Kistler-Nitschmann procedures) is used to isolate the immunoglobulin-containing fraction. This is followed by further purification techniques, including additional precipitation steps to remove non-immunoglobulin G (IgG) proteins and ion exchange chromatography to further separate and purify the desired IgG. </p><p>Most <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> preparations also undergo several specific treatments to inactivate or remove bloodborne pathogens that could be present. These include low pH treatment, fatty acid/alcohol treatment, solvent-detergent treatment, and/or heat treatment (pasteurization). All products undergo nanofiltration or depth filtration to remove potential prions from the donor plasma pool. These processes are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Infectious risks'</a>.)</p><p>The World Health Organization has published minimum standards for manufacturing <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> preparations [<a href="#rid39">39,40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> should be extracted from a pool of at least 1000 individual donors</p><p class="bulletIndent1"><span class="glyph">●</span>It should contain as little IgA as possible</p><p class="bulletIndent1"><span class="glyph">●</span>It should be free from preservatives or stabilizers that might accumulate in vivo</p><p class="bulletIndent1"><span class="glyph">●</span>The IgG molecules should have as little biochemical modification as possible and possess opsonizing and complement-fixing activities</p><p></p><p>The preparations contain highly purified (generally &gt;95 percent) polyvalent IgG. However, there are slight differences in the manufacturing procedures used by different producers, and different stabilizers (eg, sucrose, glucose, maltose) are used in the excipients  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>). Many available products use amino acids such as glycine or proline to stabilize or prevent aggregation of the IgG molecules in <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. The sodium content of different products also varies. Products also differ in storage requirements and shelf life.</p><p>These refinements were made following the experience with earlier <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> preparations used in the 1950s and 1960s, which were effective in treating sepsis and viral infections but were associated with severe anaphylactic reactions thought to be due to highly vasoactive peptides and IgG aggregates [<a href="#rid41">41-43</a>].</p><p>Viral inactivation processes such as solvent/detergent treatment are effective in inactivating lipid-enveloped viruses (eg, HIV, HBV, HCV, EBV, CMV) but not non-lipid enveloped viruses such as hepatitis A virus and parvovirus B19; however, the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> product is likely to contain antibodies to these viruses that might reduce their pathogenicity. Viral inactivation processes and infectious risks of IVIG are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Infectious risks'</a> and  <a class="medical medical_review" href="/z/d/html/7929.html" rel="external">"Pathogen inactivation of blood products", section on 'Solvent/detergent treatment'</a>.)</p><p class="headingAnchor" id="H396565"><span class="h1">SELECTING A PRODUCT</span><span class="headingEndMark"> — </span>The majority of patients tolerate most IVIG products with a minimum of adverse events. Thus, for many patients, selection of a product to conform to local dispensing or formulary preferences is appropriate, particularly when a limited duration of therapy is anticipated for an autoimmune process. However, there are some circumstances in which one product may be more suitable than another for a given patient. For example, some patients receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> can experience hemolytic anemia. Risk factors include non-O blood group, first infusion, and lack of immune suppression [<a href="#rid44">44</a>]. Low-dose therapy such as in patients with antibody deficiency is usually safe, but hemolysis has been reported [<a href="#rid45">45</a>]  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H399027"><span class="h2">Selection of IVIG versus other routes</span><span class="headingEndMark"> — </span>Most <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> products are labeled for a specific route of administration (eg, intravenous, subcutaneous, intramuscular). Several 10 percent IVIG solutions can be administered subcutaneously, and reports suggest that most intravenous products are well tolerated by the subcutaneous route [<a href="#rid46">46</a>]. By contrast, 20 percent subcutaneous and 16 percent intramuscular products are generally more concentrated than intravenous preparations and should not be given intravenously.</p><p>For individuals with immunodeficiencies, either subcutaneous or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> are both effective. The subcutaneous route causes fewer systemic adverse effects and provides less variable serum IgG levels compared with the intravenous route, as discussed separately. Additionally, the subcutaneous route has been demonstrated to be cost effective and have better quality of life measures compared with the intravenous route in patients with primary immune deficiency disease [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy", section on 'Advantages of SCIG'</a>.)</p><p>Studies are emerging on the use of subcutaneous immune globulins in individuals with autoimmune/inflammatory disorders. Several studies in neuromuscular disease have shown promising results [<a href="#rid50">50-53</a>].</p><p class="headingAnchor" id="H396592"><span class="h2">Selection among IVIG products</span><span class="headingEndMark"> — </span>Available <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> products are equally effective for the treatment of a variety of immunodeficiency and autoimmune/inflammatory states. However, products may differ from each other in ways that may be important in a particular patient. In the United States, IVIG products are supervised and licensed by the US Food and Drug Administration. Properties of products available in the United States are summarized in the table  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>).</p><p>Examples of ways in which specific products may be tailored to specific patient groups include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Certain stabilizers may be associated with adverse effects in some patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maltose or glucose</strong> – Patients with diabetes should be careful with maltose-containing products, as certain types of glucose meters cannot discriminate between maltose and glucose. Diabetics should also be careful with glucose-containing products. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sucrose</strong> – Products that contain sucrose are no longer available in the United States. Sucrose-containing products were previously observed to cause an increased risk of osmotic renal injury [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Complications affecting the kidney'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">Sorbitol</a> – Sorbitol-containing products must not be administered to subjects with hereditary fructose intolerance (HFI). The incidence of HFI is estimated at 1 in 20,000 births and is usually diagnosed at the time of weaning when fructose or sucrose is introduced into the diet. Clinical symptoms include recurrent vomiting, abdominal pain and hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children", section on 'Hereditary fructose intolerance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have trouble tolerating increased intravascular volume may do better with preparations that are low in sodium and albumin. Some products may contain as much as 30 mg/mL (3 percent) albumin, in addition to the IgG itself, although most newer products contain lower sodium concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some products contain higher titers of antibodies to human blood group antigens than other products, particularly the ABO type "A" antigen. This may cause a positive direct antiglobulin test (DAT; Coombs), although clinically significant hemolysis is extremely rare in patients receiving low-dose Ig [<a href="#rid57">57,58</a>]. However, hemolytic anemia occurs in patients receiving high-dose <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> with an incidence as high as 5.8 percent [<a href="#rid59">59,60</a>]. Certain chromatography steps may be used to reduce isohemagglutinins [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Hemolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The variability in IgA levels may be important in individuals with absent IgA who have developed IgE-anti-IgA antibodies, which have been rarely implicated in causing anaphylaxis to IgA-containing blood products including IVIG in patients who are receiving IVIG for other conditions (eg, autoimmune/inflammatory disorders or severe antibody deficiency). The requirement for a product low in IgA is unpredictable and infrequent, as most IgA-deficient patients tolerate products that contain IgA. Most clinicians choose an immunoglobulin product with very low IgA content when treating an autoimmune process in a patient with undetectable levels (&lt;7 mg/dL) of IgA. If anti-IgA antibodies in a patient are a concern, subcutaneous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (SCIG) is an alternative to IVIG in patients with primary immunodeficiency disease [<a href="#rid62">62,63</a>]. There is no indication to give IVIG to patients as therapy for selective IgA deficiency. (See  <a class="medical medical_review" href="/z/d/html/3936.html" rel="external">"Selective IgA deficiency: Management and prognosis", section on 'Immune globulin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Products may have variable titers to less common infectious agents, such as strains of enterovirus, which may be important if the product is used to control enterovirus encephalitis. (See  <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hyperprolinemia should not be given proline-containing products, due to a theoretic risk of exacerbating their condition. However, adverse effects due to proline or other amino acid stabilizers have not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It used to be thought that patients at risk for thrombotic complications (eg, patients who are bedridden or have cryoglobulinemia, monoclonal gammopathies, or elevated lipoprotein concentrations) should receive preparations with lower osmolality. However, it is thought that activated coagulation factor XI (FXIa) in the preparations were responsible for thromboembolic complications, and adequate hydration is the most important intervention to minimize this risk [<a href="#rid64">64-68</a>]. Manufacturers use manufacturing processes to remove thrombogenic coagulation factors and test products for procoagulant activity to minimize this risk [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Thromboembolic events'</a>.)</p><p></p><p>Although most people tolerate most products, once a patient has found a product that is well tolerated, it is advisable not to change products unless there is a compelling reason to do so; administration of alternative products should only be done with the clinician's approval [<a href="#rid70">70</a>]. If an alternative product must be given to a patient on chronic therapy, it is usually prudent to use slow infusion rates initially and to monitor the patient closely. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">DOSING AND ADMINISTRATION</span></p><p class="headingAnchor" id="H164152"><span class="h2">Product handling and storage</span><span class="headingEndMark"> — </span>Liquid products and reconstituted solutions of lyophilized products that have been stored in refrigerators should be allowed to come to room temperature before administration to minimize adverse events. However, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> solutions should not be microwaved or otherwise heated, because the immunoglobulin protein could become denatured, producing protein aggregates. Vigorous mixing causing excessive foaming should also be avoided. Reconstituted lyophilized products should be inspected before administration to assure that the product has been completely dissolved and that the solution is uniform. All products should be inspected for the presence of particulates and evidence of tampering before pooling or administration to the patient, and products with any evidence of particulates or broken seals should not be used.</p><p class="headingAnchor" id="H164213"><span class="h2">Home versus health care facility administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is usually administered in an infusion center or health care facility depending on the country. However, IVIG may be infused in the home setting, usually by an experienced infusion nurse. In some situations, this practice has been found to be more cost effective and result in improved quality of life measures [<a href="#rid71">71,72</a>]. </p><p>Guidelines related to the site of care specify that the decision of where to infuse the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> are based on patient experience and circumstances, and that all initial infusions and changes should be done under clinician supervision in a facility equipped to handle severe complications [<a href="#rid35">35</a>]. Certain patients may require ongoing monitoring at higher levels, whereas others may be considered for lower levels of supervision. </p><p class="headingAnchor" id="H164158"><span class="h2">Premedications</span><span class="headingEndMark"> — </span>Many patients receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> for immunoglobulin replacement therapy do not require premedication. However, some patients may receive <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or a nonsteroidal antiinflammatory drug (NSAID) to relieve and/or prevent inflammatory and anaphylactoid symptoms. The occurrence of these adverse events is not predictable in the majority of cases and likely depends on the product, route of administration (intravenous or subcutaneous), and patient status, such as whether they have an active infection [<a href="#rid73">73</a>]. </p><p>An adverse reaction to IVIG requiring premedication, especially glucocorticoids, is an indication to switch to subcutaneous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (SCIG) or another IVIG product. Premedication generally is not necessary prior to administration of SCIG. (See  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy", section on 'Administration and dosing of SCIG'</a>.)</p><p>When used, these medications may be given 30 minutes prior to the infusion of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. The following doses are commonly used:</p><p>Pediatric doses apply to infants through age 11 or weight up to 35 kg. Adult doses apply to children &gt;age 11 and weight &gt;35 kg.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a>, 10 to 15 mg/kg (max 500 mg) orally for children or 650 to 1000 mg orally for adults, <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">Ibuprofen</a>, 10 mg/kg (max 400 mg) orally for children or 400 to 800 mg orally for adults</p><p></p><p>H1 antihistamines are also frequently given before or at the beginning of the infusion. <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">Diphenhydramine</a> can be given as 1 mg/kg (max 50 mg) orally, intravenously (IV), or intramuscularly (IM) for children; or 25 to 50 mg orally/IV/IM for adults.</p><p>Glucocorticoids can be given in selected patients who experience severe adverse reactions such as headaches, particularly if the first infusion was associated with a severe reaction, although glucocorticoids are generally avoided in individuals with immune deficiency. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Premedications'</a>.)</p><p>Changing <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> products is also associated with more frequent and severe adverse reactions, particularly headaches [<a href="#rid35">35,70</a>]. Their mechanism of action suggests that they might be most effective if given one to two hours before the infusion is initiated. This may be done conveniently by dosing after the preceding meal or when the patient leaves home to come to the infusion site. Commonly used oral regimens include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> in children, 0.5 to 1 mg/kg (max 40 mg), <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> in adults, 40 to 60 mg</p><p></p><p>Commonly, clinicians administer intravenous glucocorticoids (instead of oral) as soon as IV access is established and then wait 30 minutes before beginning the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> infusion. The following agents and doses can be used in this manner:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a>, 0.5 to 1 mg/kg (max 40 mg) IV in children or 40 to 60 mg IV in adults, <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> sodium succinate, 2 mg/kg IV in children or 100 mg IV in adults</p><p></p><p></p><p class="headingAnchor" id="H164176"><span class="h2">Prehydration</span><span class="headingEndMark"> — </span>Patients receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> should be well hydrated prior to the infusion. This is particularly important for patients with risk factors for thrombosis and/or renal complications of IVIG therapy, such as pre-existing renal insufficiency, diabetes mellitus, age greater than 65 years, paraproteinemia, heart disease, and concomitant use of nephrotoxic agents. Hydration should be given before IVIG preparations containing sucrose, as well.</p><p>Hydration can be accomplished by ample oral fluid intake or by administration of intravenous fluids before giving the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. Clinicians may administer intravenous fluids before starting high-dose IVIG, as therapy may be associated with adverse effects due to hyperviscosity. Preparations containing sucrose were associated with osmotic renal damage, although these preparations are no longer available. Normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> 10 to 20 mL/kg is suggested for this purpose. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Complications affecting the kidney'</a>.)</p><p class="headingAnchor" id="H3007160"><span class="h2">Dosing in different disorders</span><span class="headingEndMark"> — </span>Dosing varies depending upon whether the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is administered for the purpose of preventing infections in immunodeficient patients or for suppression of an inflammatory or autoimmune process.</p><p class="headingAnchor" id="H344283702"><span class="h3">Immune deficiencies</span><span class="headingEndMark"> — </span>IVIG doses in the range of 400 to 800 mg/kg/month are usually used for replacement therapy in patients with immune deficiencies. Doses may be given every three to four weeks. Typical starting doses are in the range of 400 to 600 mg/kg. Lower weekly doses are used for subcutaneous immunoglobulin replacement therapy (eg, 100 to 150 mg/kg weekly) [<a href="#rid35">35,74</a>]. The use of subcutaneous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (SCIG), including hyaluronidase- and non-hyaluronidase-containing preparations, is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy", section on 'Administration and dosing of SCIG'</a>.)</p><p>In a meta-analysis of data from clinical trials of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> therapy in patients with primary antibody deficiency, a strong correlation was identified between increasing trough IgG serum levels and decreasing pneumonia [<a href="#rid75">75</a>]. The incidence of pneumonia declined by 27 percent for each 100 mg/dL increase in IgG trough level. A subsequent meta-regression analysis showed a decrease in infection rates by 13 percent for every 100 mg/dL increment of IgG trough up to 960 mg/dL; IgG trough levels increased by 73 mg/dL for every 100 mg/kg dose increase in IVIG [<a href="#rid76">76</a>].</p><p>Dosing of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> can be adjusted depending on the patient's progress (eg, frequency of infections). Some patients may need higher or more frequent doses to remain free from acute infections; to control chronic infections, particularly of the sinopulmonary tract; and/or to maintain target serum immunoglobulin G (IgG) levels [<a href="#rid77">77</a>]. Prophylactic antibiotics may be indicated in some cases to prevent the need for escalating doses of IVIG. Dosing is quite variable among patients, in that each patient may have their own dosing requirements, but most are best served by using trough or steady-state IgG levels approaching physiologic serum IgG levels [<a href="#rid71">71,77</a>]. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity", section on 'Individualizing the dose'</a>.)</p><p>Compared with subcutaneous dosing given more frequently, IV dosing yields lower serum trough levels of IgG at the end of each dosing interval as the time for the next dose nears. Some patients will become more susceptible to infections during this period or feel otherwise unwell; this is commonly called "wear-off." (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H344283712"><span class="h3">Inflammatory/autoimmune disorders</span><span class="headingEndMark"> — </span>In patients who require the antiinflammatory or immunomodulatory properties of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, intravenous administration of high doses are usually required. As an example, patients with Kawasaki disease are usually given 2 grams/kg as a single dose. In older patients and those with underlying conditions that may predispose to thrombosis and other complications, we give therapeutic doses of IVIG larger than 1 gram/kg in multiple increments divided over several consecutive days so that no more than 500 mg/kg is given in a 24-hour period. (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Intravenous immune globulin'</a>.)</p><p>Dosing for specific diseases is discussed in the appropriate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune thrombocytopenia – (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'IVIG dosing and administration'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Guillain-Barré syndrome (children) – (See  <a class="medical medical_review" href="/z/d/html/6204.html" rel="external">"Guillain-Barré syndrome in children: Treatment and prognosis", section on 'Intravenous immune globulin'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Guillain-Barré syndrome (adults) – (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Immune globulin'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic inflammatory demyelinating polyneuropathy – (See  <a class="medical medical_review" href="/z/d/html/5265.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis", section on 'Intravenous immune globulin'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Kawasaki disease – (See  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis", section on 'Intravenous immune globulin'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic parvovirus infection with anemia – (See  <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">"Treatment and prevention of parvovirus B19 infection", section on 'Chronic infection with anemia'</a>.)</p><p></p><p class="headingAnchor" id="H163953"><span class="h2">Interval between doses</span><span class="headingEndMark"> — </span>Serum trough levels of IgG or steady state serum IgG levels are often used as one criterion of the adequacy of treatment in patients with antibody deficiency diseases receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>; most patients are best served by using trough or steady state IgG levels in the physiologic range. Other approaches include measuring specific antibodies to pneumococcal polysaccharides or the IgG3 subclass, since this IgG subclass has the shortest half-life. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity", section on 'Trough levels'</a>.) </p><p>The rationale for measuring trough levels (or steady state IgG levels) is that the rate of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> metabolism may vary with the clinical state. One study, for example, evaluated 15 patients with chronic lymphocytic leukemia who were given 400 mg/kg of IVIG every three weeks; the mean half-life was 39.1 days (standard deviation = 9.6 days) [<a href="#rid78">78</a>]. This is longer than the half-life of approximately three to four weeks observed in patients with primary immunodeficiencies or in healthy volunteers given IVIG. The rate of metabolism does not appear to increase with chronic administration. However, detailed pharmacokinetic studies are not available in patients with autoimmune diseases given repeated high dosages of IVIG.</p><p>In contrast, it is not established that measurement of IgG levels is relevant in patients with autoimmune disorders, where the endpoint is clinical improvement.</p><p class="headingAnchor" id="H164067"><span class="h2">Infusion rates</span><span class="headingEndMark"> — </span>Many infusion-related adverse effects are associated with the rate of administration. Therefore, it is customary to start each IVIG infusion at a slow rate, such as 0.01 mL/kg per minute, which would provide 0.5 or 1 mg/kg of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> per minute depending upon whether a 5 or 10 percent solution is being infused, respectively. The infusion rate may then be increased at 20- to 30-minute intervals, while monitoring the patient closely for alterations in vital signs or subjective symptoms.</p><p>If the patient tolerates the initial infusion rate without symptoms, the rate of infusion may be increased. The specific increments and infusion rates should conform to the product information for the product being administered. We commonly increase the rate to 0.02 mL/kg per minute, then 0.04 mL/kg per minute, and in one or two additional increments until a maximum rate of 0.08 mL/kg per minute. The rate of 0.08 mL/kg per minute corresponds to 4 mg/kg per minute for a 5 percent solution (a solution of 5 grams/dL [500 mg/mL]) or 8 mg/kg per minute for a 10 percent solution (a solution of 10 grams/dL [1000 mg/mL]).</p><p>Higher rates may be tolerated in selected patients and with preparations that are low in sodium and/or free of high concentrations of sugar as stabilizers [<a href="#rid79">79</a>]. After it has been established that a given patient tolerates a certain product at a specific rate, fewer steps and/or shorter intervals may be used during the "ramp up," but patients should always be monitored closely because lot-to-lot and patient-to-patient variation in tolerability may occur.</p><p class="headingAnchor" id="H3007154"><span class="h2">Dosing in individuals with high BMI</span><span class="headingEndMark"> — </span>There is insufficient evidence upon which to base recommendations for dosing individuals with a high body mass index (BMI); there is no clearly defined standard approach. A reasonable approach would be to start with a dose based on ideal body weight (IBW) (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>) or adjusted body weight (also called dosing weight) and then modify the dose further based upon the patient's clinical response [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> products are virally inactivated, and monitoring for bloodborne infections is not routinely performed.</p><p>Routine monitoring may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>As described above, pretreatment testing is done to evaluate hematologic parameters, renal function, metabolic status, glucose, and possible infections such as hepatitis (eg, by testing hepatic transaminases). These can be repeated at six-month or yearly intervals [<a href="#rid81">81</a>]. (See <a class="local">'Pretreatment testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> products have been associated with positive Coombs (direct antiglobulin) tests (DAT) and/or frank hemolysis. Thus, when high-dose IVIG is to be given over two or more days for treating autoimmune disorders, it is prudent to check for a drop in hemoglobin and/or Coombs positivity before proceeding with the second or subsequent doses [<a href="#rid82">82,83</a>]. Hemolysis may occur in patients with antibody deficiency on immunoglobulin replacement therapy, although this is not common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a previously negative Coombs test becomes positive, one or more of the following may be done:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Switch the patient to a different <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> preparation in which isohemagglutinins have been reduced [<a href="#rid61">61</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>Delay or divide the remaining dose.</p><p class="bulletIndent2"><span class="glyph">•</span>Evaluate and/or refer to hematology for evaluation of possible new development of autoimmune hemolytic anemia, especially in individuals with certain hematologic malignancies or common variable immune deficiency.</p><p></p><p class="bulletIndent1">The patient should be well hydrated and monitored closely for hemolysis.</p><p></p><p class="headingAnchor" id="H11541199"><span class="h1">VACCINATION OF PATIENTS RECEIVING IVIG</span><span class="headingEndMark"> — </span>Administration of IVIG may interfere with the efficacy of vaccinations because the antibodies in the <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> may bind to the antigenic substance in the vaccine and interfere with the normal immune response to the vaccination, especially live-virus vaccines. In addition, individuals with underlying immune deficiency may have an immunologic defect that blunts the immune response to vaccination independent of IVIG administration. </p><p>Considerations for specific vaccines include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – The Centers for Disease Control and Prevention (CDC) in the United States has advised that administration of a COVID-19 vaccine at the same time as, or with any interval before or after <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> administration, is unlikely to impair development of an immune response to the vaccine and has stated that there is no recommended minimum interval between administration of IVIG and COVID-19 vaccination [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – Firm recommendations regarding influenza virus immunization are challenging because of a lack of comprehensive data and antigenic variability of the viruses from year to year. To the extent that new antigens arise each year, immunization with inactivated vaccine may induce some protective antibody that is not present in the donor plasma pool. Data correlating the response to inactivated influenza vaccines with the timing after <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> administration are lacking, but if the antigens in any given vaccine are unique, exogenous IVIG should not interfere with the host's ability to respond, if that is intact. IVIG is unlikely to interfere with local replication of attenuated live (nasal) vaccines, however, these are not usually recommended for immunodeficient patients. Many clinicians give <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> to patients receiving IVIG therapy to stimulate T cell immunity to the virus, which may help in recovery from influenza.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMR and varicella</strong> – The concern about <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> interference with immune response to a vaccine is particularly problematic with live-virus vaccines such as measles, mumps, and rubella (MMR) or varicella. Passively transferred IgG may prevent viral replication, which is necessary for inducing the desired immune response. This effect may persist for months after receiving IVIG. The American Academy of Pediatrics has made specific recommendations for administration of live vaccines against measles and varicella in individuals receiving IVIG. (See  <a class="medical medical_review" href="/z/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Recent receipt of blood or immune globulin'</a> and  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Recent receipt of immune globulin or blood'</a>.)</p><p></p><p>In selected cases of vaccination during a period of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> administration for an autoimmune disorder, it may make sense to check titers following vaccination six months after IVIG has been discontinued, as a way to determine whether the patient has protective immunity and to decide to reimmunize if the titers are not protective. However, we would not discontinue IVIG in a patient with immunodeficiency solely to assess vaccine efficacy. Some centers have used a neoantigen vaccine such as <em>Salmonella</em> Typhi Vi, in which the immunoglobulin products do not contain specific antibodies for diagnostic use, to assess the ability of the patient to produce specific antibodies even while receiving immunoglobulin replacement therapy [<a href="#rid85">85</a>]. </p><p class="headingAnchor" id="H164407"><span class="h1">CONSENT AND RECORD KEEPING</span><span class="headingEndMark"> — </span>Some institutions require signed consent before any blood product or blood derivative is administered. Documentation in the records that potential risks (see  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>) have been explained and that the patient/parent has received this information, has been given the opportunity to ask questions, and has given consent to receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> before initiating therapy is often only necessary. Appropriate institutional protocols should be followed.</p><p>The dose, brand, lot number, expiration date, and manufacturer of any <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> product infused into any patient should be recorded in the medical record. In addition, patients should be encouraged to keep their own logs of this information, in case a "look back" is ordered. Most vials of IVIG have a perforated sticker that can be removed and kept in the patient's personal log book, or the lot number can be requested from the hospital pharmacy or other provider.</p><p class="headingAnchor" id="H2622063"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Adverse effects of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p class="headingAnchor" id="H4179277650"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105473.html" rel="external">"Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117890.html" rel="external">"Society guideline links: Myasthenia gravis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114912.html" rel="external">"Society guideline links: Guillain-Barré syndrome"</a>.)</p><p class="headingAnchor" id="H722804566"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_patient" href="/z/d/html/106356.html" rel="external">"Patient education: Intravenous immune globulin (IVIG) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Actions</strong> – The mechanism of intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) action depends on the indication for which it is given (see <a class="local">'Mechanisms of action'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> – IVIG has a number of immunosuppressive and antiinflammatory properties that include modulation of immunoglobulin G (IgG) levels, lymphocyte and reticuloendothelia function, cytokine production, complement regulation, and clearance of pathogenic IgG. IVIG provides adequate concentrations of antibodies against a broad range of pathogens for patients with hypogammaglobulinemia, antibody deficiency disorders, other immunodeficiency states, and certain infections. (See <a class="local">'Uses for IVIG'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperimmune globulins</strong> – Hyperimmune globulins provide specific passive immunity, typically in the setting of a known or expected exposure. The use of hyperimmune globulin in the 2019-2020 coronavirus disease (COVID-19) pandemic is under investigation, although it is unlikely to be manufactured at scale unless convalescent plasma appears to be effective. (See <a class="local">'Uses for hyperimmune globulin'</a> above and  <a class="medical medical_review" href="/z/d/html/128321.html" rel="external">"COVID-19: Convalescent plasma and hyperimmune globulin"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uses</strong> – There are numerous uses for <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>. Selected examples (not intended as an exhaustive list) are noted above, with details of the indications and administration in separate topic reviews. Selected uses for hyperimmune globulin are also listed above. (See <a class="local">'Clinical uses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment testing</strong> – For most patients, we obtain a pretreatment complete blood count (CBC), hepatic transaminases, metabolic panel including glucose, serum creatinine, and urinalysis. Patients with abnormalities in this testing may require additional evaluation. (See <a class="local">'Pretreatment testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of product</strong> – <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is produced from pooled plasma donated by several thousand screened donors. Numerous quality control procedures and manufacturing standards are in place to ensure highly purified and stable solutions, although slight differences exist among products  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>). Choice of product depends on patient and disease factors and clinical judgment. Individuals who require a specific type of hyperimmune globulin should receive a product intended for this purpose rather than IVIG. Once a patient has found a well-tolerated IVIG product, it is advisable not to change products without a compelling reason; administration of alternative products should only be done with the clinician's approval. (See <a class="local">'Production and composition'</a> above and <a class="local">'Selecting a product'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Dosing in different disorders, interval between doses, use of premedication, and infusion rates depend on patient and/or disease factors. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – The decision where to infuse a patient (hospital, office, or home) depends on clinical considerations and patient preference. Certain patients require higher levels of monitoring and intervention during <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> infusions. (See <a class="local">'Home versus health care facility administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Record keeping</strong> – The dose, brand, lot number, expiration date, and manufacturer of any <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> product infused into any patient should be recorded in the medical record, as done for blood products. Some institutions also require informed consent for IVIG. (See <a class="local">'Consent and record keeping'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H2512328479"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor, and Arthur J Silvergleid, MD, who contributed as author, to earlier versions of this topic review.</p><p>UpToDate also gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86:192.</a></li><li><a class="nounderline abstract_t">Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139:159.</a></li><li><a class="nounderline abstract_t">Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367:2015.</a></li><li><a class="nounderline abstract_t">Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127:315.</a></li><li><a class="nounderline abstract_t">Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 2014; 14:509.</a></li><li><a class="nounderline abstract_t">Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095.</a></li><li><a class="nounderline abstract_t">Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484.</a></li><li><a class="nounderline abstract_t">Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110.</a></li><li><a class="nounderline abstract_t">Norris PAA, Kaur G, Lazarus AH. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases. Curr Opin Hematol 2020; 27:392.</a></li><li><a class="nounderline abstract_t">Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254.</a></li><li><a class="nounderline abstract_t">Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115:679.</a></li><li><a class="nounderline abstract_t">Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359:307.</a></li><li><a class="nounderline abstract_t">Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol 2011; 139:122.</a></li><li><a class="nounderline abstract_t">Turhan A, Jenab P, Bruhns P, et al. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004; 103:2397.</a></li><li><a class="nounderline abstract_t">Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490.</a></li><li><a class="nounderline abstract_t">Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670.</a></li><li><a class="nounderline abstract_t">Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105:19571.</a></li><li><a class="nounderline abstract_t">Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106:4788.</a></li><li><a class="nounderline abstract_t">McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55:77.</a></li><li><a class="nounderline abstract_t">Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 1993; 91:602.</a></li><li><a class="nounderline abstract_t">Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631.</a></li><li><a class="nounderline abstract_t">Ashkenazi S, Cleary TG, Lopez E, Pickering LK. Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr 1988; 113:1008.</a></li><li><a class="nounderline abstract_t">Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991; 35:98.</a></li><li><a class="nounderline abstract_t">Spycher M, Matozan K, Minnig K, et al. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. Vox Sang 2009; 97:348.</a></li><li><a class="nounderline abstract_t">Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9:431.</a></li><li><a class="nounderline abstract_t">Othy S, Hegde P, Topçu S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol 2013; 190:4535.</a></li><li><a class="nounderline abstract_t">Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A 2015; 112:E2385.</a></li><li><a class="nounderline abstract_t">Trinath J, Hegde P, Sharma M, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 2013; 122:1419.</a></li><li><a class="nounderline abstract_t">Olivito B, Taddio A, Simonini G, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010; 28:93.</a></li><li><a class="nounderline abstract_t">Burns JC, Touma R, Song Y, et al. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. Autoimmunity 2015; 48:181.</a></li><li><a class="nounderline abstract_t">Tjon AS, Tha-In T, Metselaar HJ, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 2013; 173:259.</a></li><li><a class="nounderline abstract_t">Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227.</a></li><li><a class="nounderline abstract_t">Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98:3136.</a></li><li><a class="nounderline abstract_t">Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747.</a></li><li><a class="nounderline abstract_t">Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139:S1.</a></li><li><a class="nounderline abstract_t">Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46:741.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT04264858 (Accessed on April 05, 2020).</li><li><a class="nounderline abstract_t">Cao W, Liu X, Bai T, et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis 2020; 7:ofaa102.</a></li><li><a class="nounderline abstract_t">Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bull World Health Organ 1982; 60:43.</a></li><li class="breakAll">Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO technical Report Series 1989, No. 786, Annex 4.</li><li><a class="nounderline abstract_t">Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002; 2:368.</a></li><li><a class="nounderline abstract_t">BRUTON OC. Agammaglobulinemia. Pediatrics 1952; 9:722.</a></li><li><a class="nounderline abstract_t">Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17:241.</a></li><li><a class="nounderline abstract_t">Pendergrast J, Armali C, Callum J, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Transfusion 2021; 61:1053.</a></li><li><a class="nounderline abstract_t">Späth PJ, Granata G, La Marra F, et al. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol 2015; 6:11.</a></li><li><a class="nounderline abstract_t">Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 1998; 101:848.</a></li><li><a class="nounderline abstract_t">Ducruet T, Levasseur MC, Des Roches A, et al. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2013; 131:585.</a></li><li><a class="nounderline abstract_t">Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936.</a></li><li><a class="nounderline abstract_t">Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica 2014; 99:1101.</a></li><li><a class="nounderline abstract_t">Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009; 158 Suppl 1:51.</a></li><li><a class="nounderline abstract_t">van Schaik IN, van Geloven N, Bril V, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials 2016; 17:345.</a></li><li><a class="nounderline abstract_t">Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol 2017; 24:412.</a></li><li><a class="nounderline abstract_t">Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. Muscle Nerve 2017; 55:802.</a></li><li><a class="nounderline abstract_t">Ahsan N, Wiegand LA, Abendroth CS, Manning EC. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996; 16:532.</a></li><li><a class="nounderline abstract_t">Chacko B, John GT, Balakrishnan N, et al. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006; 28:193.</a></li><li><a class="nounderline abstract_t">Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55:148.</a></li><li><a class="nounderline abstract_t">Berg R, Shebl A, Kimber MC, et al. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion 2015; 55 Suppl 2:S36.</a></li><li><a class="nounderline abstract_t">Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171.</a></li><li><a class="nounderline abstract_t">Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993.</a></li><li><a class="nounderline abstract_t">Lakkaraja M, Jin JC, Manotas KC, et al. Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. Transfusion 2016; 56:2449.</a></li><li><a class="nounderline abstract_t">Gerber S, Gaida A, Spiegl N, et al. Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: Industry-scale assessment. BioDrugs 2016; 30:441.</a></li><li><a class="nounderline abstract_t">Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122:1238.</a></li><li><a class="nounderline abstract_t">Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129:628.</a></li><li><a class="nounderline abstract_t">Ovanesov MV, Menis MD, Scott DE, et al. Association of immune globulin intravenous and thromboembolic adverse events. Am J Hematol 2017; 92:E44.</a></li><li><a class="nounderline abstract_t">Seifner A, Beck G, Bayer P, et al. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography. Transfusion 2014; 54:376.</a></li><li class="breakAll">http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM258022.pdf (Accessed on August 04, 2015).</li><li><a class="nounderline abstract_t">Ammann EM, Jones MP, Link BK, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 2016; 127:200.</a></li><li><a class="nounderline abstract_t">Bennett CL, Hermanson T. Big data, thromboembolism, and immunoglobulin. Blood 2016; 127:171.</a></li><li><a class="nounderline abstract_t">Park DH, Kang GB, Kang DE, et al. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations. Biologicals 2017; 45:1.</a></li><li><a class="nounderline abstract_t">Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 2004; 136:111.</a></li><li><a class="nounderline abstract_t">Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.</a></li><li><a class="nounderline abstract_t">Hachulla E. [IgIV at home:experience of a center--economic aspects]. Rev Med Interne 2007; 28 Spec No. 1:7.</a></li><li><a class="nounderline abstract_t">Brennan VM, Salomé-Bentley NJ, Chapel HM, Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133:247.</a></li><li><a class="nounderline abstract_t">Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline. Transfus Med Rev 2010; 24 Suppl 1:S28.</a></li><li><a class="nounderline abstract_t">Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137:21.</a></li><li><a class="nounderline abstract_t">Lee JL, Mohamed Shah N, Makmor-Bakry M, et al. A Systematic Review and Meta-regression Analysis on the Impact of Increasing IgG Trough Level on Infection Rates in Primary Immunodeficiency Patients on Intravenous IgG Therapy. J Clin Immunol 2020; 40:682.</a></li><li><a class="nounderline abstract_t">Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210.</a></li><li><a class="nounderline abstract_t">Chapel HM, Lee M. Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism. J Clin Immunol 1992; 12:17.</a></li><li><a class="nounderline abstract_t">Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010; 9:553.</a></li><li><a class="nounderline abstract_t">Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol 2017; 188:353.</a></li><li><a class="nounderline abstract_t">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li><a class="nounderline abstract_t">Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: A case series analysis. Transfusion 2008; 48:1598.</a></li><li><a class="nounderline abstract_t">Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion 2015; 55:1067.</a></li><li class="breakAll">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (Accessed on December 17, 2021).</li><li><a class="nounderline abstract_t">Sánchez-Ramón S, de Gracia J, García-Alonso A, et al. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency. Clin Immunol 2016; 169:80.</a></li></ol></div><div id="topicVersionRevision">Topic 4431 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934588" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7927410" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23171098" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intravenous immune globulin in autoimmune and inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185071" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25337683" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mechanisms of immune regulation by IVIG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493456" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685887" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32868670" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6803159" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11736954" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635437" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The antiinflammatory IgG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300572" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630831" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774279" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888140" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036920" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identification of a receptor required for the anti-inflammatory activity of IVIG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261857" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544350" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Toxic shock syndrome and bacterial superantigens: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432865" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9524835" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3057156" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2032403" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656348" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612546" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23526819" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870292" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23847198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412712" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25822882" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607448" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9895405" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698302" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547745" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041678" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Update on the use of immunoglobulin in human disease: A review of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686841" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686841" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32258207" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979419" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979419" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165202" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14929630" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571392" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risks associated with the use of intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433931" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25699039" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : On the dark side of therapies with immunoglobulin concentrates: the adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9648714" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040368" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480339" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682509" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19883424" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Subcutaneous immunoglobulin: opportunities and outlook.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27455854" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28000311" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27649063" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955767" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Acute renal failure following immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538981" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628320" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26174896" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835249" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adverse effects of human immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833910" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27611703" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27646589" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: Industry-scale assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842292" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intravenous immunoglobulin: adverse reactions and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835445" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28066925" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Association of immune globulin intravenous and thromboembolic adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772713" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772713" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443622" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769768" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Big data, thromboembolism, and immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876270" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15030521" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Increased risk of adverse events when changing intravenous immunoglobulin preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471071" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768832" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : [IgIV at home:experience of a center--economic aspects].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12869031" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19962579" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675197" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32417999" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A Systematic Review and Meta-regression Analysis on the Impact of Increasing IgG Trough Level on Infection Rates in Primary Immunodeficiency Patients on Intravenous IgG Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18602574" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551938" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346419" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263379" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Considerations for dosing immunoglobulin in obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466176" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: A case series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25532440" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25532440" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27236002" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
